The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).
 
Pedro Isaacsson Velho
Honoraria - Bayer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Pfizer
Research Funding - Bristol-Myers Squibb; Pfizer (Inst)
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Merck; Merck Serono; Pfizer
 
Nooshin Mirkheshti
No Relationships to Disclose
 
Fahad Qazi
No Relationships to Disclose
 
Farah Shaukat
No Relationships to Disclose
 
Wei Fu
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Mark Christopher Markowski
No Relationships to Disclose
 
Samuel R. Denmeade
Stock and Other Ownership Interests - Sophiris Bio
Consulting or Advisory Role - Sophiris Bio
Travel, Accommodations, Expenses - Sophiris Bio
 
Catherine Handy Marshall
Research Funding - Conquer Cancer Foundation/Bristol-Myyers Squibb
 
Tamara L. Lotan
Consulting or Advisory Role - Janssen Oncology
Research Funding - Ventana Medical Systems
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru; Veru; Veru
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi; Veru
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi